# Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection

> **NCT04219865** · PHASE1 · COMPLETED · sponsor: **Nanjing Yoko Biomedical Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Group 1: Compound Edaravone/Placebo Injection
- **DRUG:** Group 2: Compound Edaravone/Placebo Injection
- **DRUG:** Group 3: Compound Edaravone/Placebo Injection
- **DRUG:** Group 4: Compound Edaravone/Placebo Injection
- **DRUG:** Group 5: Compound Edaravone/Placebo Injection

## Key facts

- **NCT ID:** NCT04219865
- **Lead sponsor:** Nanjing Yoko Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-05
- **Primary completion:** 2019-08-16
- **Final completion:** 2019-08-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04219865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04219865, "Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04219865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*